Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024

By sjmartinez • August 7, 2024

Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, Gaglani M, Columbus C, Gottlieb RL, Ghamande S, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Saeed S, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Khan A, Hough CL, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Parikh B, Exline MC, Vaughn IA, Ramesh M, Safdar B, Mosier J, Harris ES, Shapiro NI, Felzer J, Zhu Y, Grijalva CG, Halasa N, Chappell JD, Womack KN, Rhoads JP, Baughman A, Swan SA, Johnson CA, Rice TW, Casey JD, Blair PW, Han JH, Ellington S, Lewis NM, Thornburg N, Paden CR, Atherton LJ, Self WH, Dawood FS, DeCuir J. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Clin Infect Dis. 2024 Aug 6:ciae405. doi: 10.1093/cid/ciae405. Epub ahead of print. PMID: 39107255.

Tags: COVID-19 severity, COVID-19 vaccine effectiveness, JN.1 and BA.2.86, Publications, Pulmonary, Critical Care & Sleep Medicine, SARS-CoV-2 variants, test-negative design

Device-Specific Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: Insights From the Multicenter CLEAR-IE Registry

Robinson G, Heybati K, Hibbert B, Bangalore S, Fong P, Zlotnick D, Zwischenberger B, Sayfo S, Younes S, Ingrassia J, Hammadah M, Prasad A, Hamid[...]

State-level paid sick leave: impacts of policy design on access by immigrant workers

Luo Z, Sprague A, McCormack M, Heymann J. State-level paid sick leave: impacts of policy design on access by immigrant workers. Health Aff Sch. 2026[...]

Multiorgan Toxicity Following Rifapentine and Isoniazid Therapy for Latent Tuberculosis Infection: A Case Report

Parvini Najafabadi S, Ramesh K, Tu B, Fiske B, Meyer N. Multiorgan Toxicity Following Rifapentine and Isoniazid Therapy for Latent Tuberculosis Infection: A Case Report.[...]